Approval Of Novartis' Everolimus Could Mean mTOR Inhibitor Class REMS

The likely approval of Novartis' everolimus for prevention of kidney transplant rejection could bring with it safety labeling updates and Risk Evaluation and Mitigation Strategies for all drugs in the mTOR inhibitor class